Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial looked at a cream called delgocitinib, tested at four different strengths (1, 3, 8, and 20 mg/g), compared against a "vehicle" cream containing no active ingredient. The trial enrolled 251 people in total across the five groups, and measured changes in their eczema (atopic dermatitis) symptoms over 8 weeks. The main thing being measured was a skin scoring system called the EASI, which runs from 0 to 72 — a higher number means more severe or widespread eczema. The reported data shows that after 8 weeks, the average EASI score fell by 5.0 points in the 1 mg/g group, 4.9 points in the 3 mg/g group, 5.8 points in the 8 mg/g group, and 7.6 points in the 20 mg/g group, compared to a fall of 1.9 points in the vehicle (no active ingredient) group. For a secondary measure — the number of participants whose skin was rated "clear" or "almost clear" with a meaningful improvement by a doctor — the reported figures were 9, 14, 15, and 24 participants across the four increasing dose groups respectively, versus 5 participants in the vehicle group. The reported data also shows that 20, 21, 28, and 33 participants in each dose group (compared to 10 in the vehicle group) achieved at least a 75% reduction in their EASI score by week 8. For the time taken to reach a "clear" or "almost clear" rating, the data was not reported for the 3 mg/g and vehicle groups; for the other groups, the reported median times were 64 days for the 1 mg/g group, 64 days for the 8 mg/g group, and 44 days for the 20 mg/g group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older
- You have been diagnosed with atopic dermatitis (eczema) using a specific set of recognised medical criteria
- You have had atopic dermatitis for at least 1 year
- Your atopic dermatitis affects between 5% and 50% of your body surface area (not counting the scalp) at the time of screening and at the start of the trial
- Your atopic dermatitis is rated as at least mild in severity based on a standard medical scale at the time of screening and at the start of the trial
Who may not be able to join:
- You have atopic dermatitis patches on your scalp at the time of screening or the start of the trial
- You have another active skin condition that could be confused with atopic dermatitis or make it hard to assess treatment, such as scabies, a type of skin lymphoma, rosacea, hives, or psoriasis
- You have a known allergic or irritant skin reaction that is likely to interfere with measuring how severe your atopic dermatitis is
- You have used tanning beds or light therapy within 4 weeks before the start of the trial
- You have taken immune-suppressing or immune-modifying medicines, or steroid tablets/injections, within 4 weeks before the start of the trial, or you have had 3 or more bleach baths in any single week during the 4 weeks before the start of the trial
- You have used steroid creams or ointments, certain other prescribed skin creams, or oral antibiotics within 2 weeks before the start of the trial
- You have started taking antihistamines or changed your antihistamine dose within 2 weeks before the start of the trial
- You have received a live vaccine within 4 weeks before the start of the trial
- You have been treated with certain biological medicines (either approved or experimental) within 6 months or 5 half-lives before the start of the trial, whichever period is longer, or until your blood cell counts return to normal
- You have had any active skin infection within 1 week before the start of the trial
- You have had a significant infection — such as a serious whole-body or skin infection requiring treatment through a drip or injection — within 4 weeks before the start of the trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Expert, LEO Pharma
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Change From Baseline (Week 0) to Week 8 in Eczema Area and Severity Index (EASI) Score.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.